These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31647396)

  • 41. Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.
    Ryan P; Patel B; Makwana V; Jadhav HR; Kiefel M; Davey A; Reekie TA; Rudrawar S; Kassiou M
    ACS Chem Neurosci; 2018 Jul; 9(7):1530-1551. PubMed ID: 29782794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of Serum Exosomes from a Transgenic Mouse Model of Alzheimer's Disease.
    Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Ali SF; Hanig J; Sarkar S
    Curr Alzheimer Res; 2019; 16(5):388-395. PubMed ID: 30907317
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alzheimer's pathogenesis and its link to the mitochondrion.
    Simoncini C; Orsucci D; Caldarazzo Ienco E; Siciliano G; Bonuccelli U; Mancuso M
    Oxid Med Cell Longev; 2015; 2015():803942. PubMed ID: 25973139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel disease-modifying therapies for Alzheimer's disease.
    Jiang T; Yu JT; Tan L
    J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Mechanisms of Dietary Phytoestrogen as a Potential Treatment and Prevention Agent against Alzheimer's Disease.
    Hussain A; Tabrez ES; Muhammad A; Peela JR
    Crit Rev Eukaryot Gene Expr; 2018; 28(4):321-327. PubMed ID: 30311580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiaggregation Potential of Padina gymnospora against the Toxic Alzheimer's Beta-Amyloid Peptide 25-35 and Cholinesterase Inhibitory Property of Its Bioactive Compounds.
    Shanmuganathan B; Sheeja Malar D; Sathya S; Pandima Devi K
    PLoS One; 2015; 10(11):e0141708. PubMed ID: 26536106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
    Wozniak MA; Frost AL; Itzhaki RF
    Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding the cause of sporadic Alzheimer's disease.
    Zetterberg H; Mattsson N
    Expert Rev Neurother; 2014 Jun; 14(6):621-30. PubMed ID: 24852227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function -- role of glucose metabolism and insulin signalling.
    Rhein V; Eckert A
    Arch Physiol Biochem; 2007 Jun; 113(3):131-41. PubMed ID: 17922309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Implications of Autophagy in Alzheimer's Disease.
    Hamano T; Hayashi K; Shirafuji N; Nakamoto Y
    Curr Alzheimer Res; 2018; 15(14):1283-1296. PubMed ID: 30289076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural Products as Potential Anti-Alzheimer Agents.
    Panda SS; Jhanji N
    Curr Med Chem; 2020; 27(35):5887-5917. PubMed ID: 31215372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Misfolded proteins as a therapeutic target in Alzheimer's disease.
    Liyanage SI; Weaver DF
    Adv Protein Chem Struct Biol; 2019; 118():371-411. PubMed ID: 31928732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Beginnings in Alzheimer's Disease: The Most Prevalent Tauopathy.
    Hernández F; Llorens-Martín M; Bolós M; Pérez M; Cuadros R; Pallas-Bazarra N; Zabala JC; Avila J
    J Alzheimers Dis; 2018; 64(s1):S529-S534. PubMed ID: 29562521
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-amyloid treatments in Alzheimer's disease.
    Sapra M; Kim KY
    Recent Pat CNS Drug Discov; 2009 Jun; 4(2):143-8. PubMed ID: 19519562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
    Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L
    Science; 2007 May; 316(5825):750-4. PubMed ID: 17478722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathological Impacts of Chronic Hypoxia on Alzheimer's Disease.
    Zhang F; Niu L; Li S; Le W
    ACS Chem Neurosci; 2019 Feb; 10(2):902-909. PubMed ID: 30412668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
    Thal DR; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.